StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $0.21 | $0.20 | -2.61% | 0.8M |
| 05-12 | $0.20 | $0.20 | -1.25% | 0.6M |
| 05-13 | $0.19 | $0.19 | -2.11% | 1.4M |
| 05-14 | $0.18 | $0.19 | +4.36% | 0.6M |
| 05-15 | $0.19 | $0.19 | +1.16% | 0.4M |
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
No sell-side coverage available for BRTX.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
Fundamentals not available for BRTX.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $23.17K | $359.70K | $340.10K | $328.30K |
Operating Income | $-3.39M | $-15.65M | $-11.82M | $-8.11M |
Net Income | $-2.15M | $-14.24M | $-11.03M | $-2.66M |
EPS (Diluted) | $-0.12 | $-1.58 | $-1.26 | $-0.94 |
Total Assets | $4.64M | $4.08M | $5.64M | $8.52M |
Total Liabilities | Not available | Not available | Not available | $3.67M |
Cash & Equivalents | $3.11M | $1.51M | $602.44K | $1.56M |
Free Cash Flow OCF − CapEx | Not available | $-10.91M | $-8.41M | $-5.51M |
Shares Outstanding | 25.48M | 8.88M | 7.98M | 7.98M |